Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Shizuru

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Transplantation and Cellular Therapy|August 29, 2025
The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024Dilek Uzun, Jeddeo Michael Paul, Alexandria Jensen, et al.
JCI Insight|May 17, 2019
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipientsEverett H Meyer, Ginna Laport, Bryan J Xie, et al.
Transplantation and Cellular Therapy|March 27, 2026
Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell TransplantationAlfonso Molina, Quenton Rashawn Bubb, Hrishikesh K Srinagesh, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Blood Advances|March 18, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicityMark P Hamilton, Erin Craig, Cesar Gentille Sanchez, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Haematologica|June 6, 2020
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesJason P Cooper, Barry E Storer, Noa Granot, et al.
Research Square|November 24, 2025
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasMark P Hamilton, Nick Phillips, Troy Noordenbos, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Transplantation and Cellular Therapy|August 29, 2025
The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024Dilek Uzun, Jeddeo Michael Paul, Alexandria Jensen, et al.
JCI Insight|May 17, 2019
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipientsEverett H Meyer, Ginna Laport, Bryan J Xie, et al.
Transplantation and Cellular Therapy|March 27, 2026
Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell TransplantationAlfonso Molina, Quenton Rashawn Bubb, Hrishikesh K Srinagesh, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Blood Advances|March 18, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicityMark P Hamilton, Erin Craig, Cesar Gentille Sanchez, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Haematologica|June 6, 2020
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesJason P Cooper, Barry E Storer, Noa Granot, et al.
Research Square|November 24, 2025
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasMark P Hamilton, Nick Phillips, Troy Noordenbos, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Pageof 3